GENCEFE BIOTECH

GENCEFE BIOTECH LIMITED was founded in 2020, and started its US branch in 2021. GenCefe focuses on the development and application of molecular biology technologies, using high-throughput, automation technology and artificial intelligence to break through the bottleneck of the gene synthesis industry. We are aiming to build an innovative synthetic biology technology and application platform, providing integrated CRO services and raw material production to meet the needs of the biomedical industry, in vitro diagnostic industry and scientific research. Our product portfolio serves researchers worldwide in cell and gene therapy, biopharmaceutical and vaccine development, etc. GenCefe's R&D team is led by Prof. Lei Kai, who is an expert of CFPS (Cell Free Protein Synthesis) and a distinguished professor of Jiangsu Province. The company has established an experienced, professional and efficient scientific team, focusing on CRO services and in vitro diagnostic (IVD) reagents core raw materials production. To comply with ISO9001 quality management standards, GenCefe adopts standardized management operations in the entire process of product development, production, packaging, storage and transportation, as well as company management and operation. We continuously optimize the production and operation procedures to provide high quality products and services to customers.